A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma

Institute Jules Bordet, Brussels

Cliniques Universitaires St Luc, Brussels

Clinique St Pierre, Ottignies

Cancer Therapy Centre, Liverpool

The Canberra Hospital Building 3, L 2, Garran

KUL, Leuven

Peter MacCallum Cancer Centre, East Melbourne

St Vincents Hospital, Fitzroy

Box Hill Hospital, 4th Floor, Clive Ward Centre, Box Hill

Monash Medical Centre, Clayton

Royal Brisbane & Women's Hospital, Herston

The Townsville Hospital, Douglas

Clinical Research Unit Cairns Base Hospital, Cairns

Royal Adelaide Hospital L3 East Wing, North Terrace

Ashford Cancer Centre, Ashford

Cliniques universitaires UCL de Mont-Godinne, Yvoir

Sir Charles Gairdner Hospital, Nedlands

Royal Hobart Hospital, Hobart

Western Pennsylvania Hospital, Pittsburgh

CHU de Dijon, Dijon

Centre Hospitalier, Valence

Hôpital Purpan, Toulouse

Polyclinique Bordeaux Nord Aquitaine, Bordeaux

Hôpital Lapeyronie, Cedex

CHU Rennes Hôpital Pontchaillou, Rennes

Hôpital Bretonneau, Tours

Hopital Michallon, Grenoble

CHU Hôtel Dieu, Nantes

CHU Hôpital Hôtel Dieu, Angers

CHRU Hôpitaux de Brabois - Hématologie, Vandœuvre-lès-Nancy

Hôpital N.D.de Bon Secours, Metz

Hôpital Claude Huriez, Place de Verdun Cedex

Hôtel Dieu Pavillon Villemur Pasteur, Clermont-Ferrand

Cancer Center of Kansas, Wichita

Centre Hospitalier Lyon Sud, Lyon Sud

Hôpital Saint-Louis, Paris

Hôpital Necker, Paris

Hôpital de la Pitié Salpétriere, Paris

Centre Henri Becquerel, Rouen

CHD Les Oudairies, La Roche-sur-Yon

CHU Dupuytren, Limoges

Centre René Huguenin, Saint-Cloud

Hopital Henri Mondor, Créteil

Tower Cancer Research Foundation, Beverly Hills

Hackensack University Medical Center, Hackensack